GSK-NPS COPD partnership
August 5, 2016
GLAXOSMITHKLINE will fund
an offshoot of NPS MedicineWise
to produce and deliver a new
education program to GPs on
chronic obstructive pulmonary
disease (COPD).
VentureWise is an “independently
run, wholly owned commercial
subsidiary of NPS MedicineWise,”
established last year to explore
commercial opportunities with
pharmaceutical manufacturers,
health insurers and other providers.
Under the new GSK deal, the
VentureWise program will aim to
“provide greater clarity to health
professionals on medicine choice
for COPD, improve adherence
and inhaler technique, and
reduce confusion associated with
medicines for COPD and asthma”.
VentureWise retains complete
independence in determining all
aspects of the design, content and
implementation of the program,
according to the organisation’s
managing director Greg Hughes.
The move follows the
introduction earlier this year of
GSK’s new framework for medical
education and interaction with
health professionals to increase
transparency.
GSK Australia medical director
Andrew Weekes said VentureWise
and GSK both recognise there
are challenges for GPs in keeping
up with advances in COPD
therapeutics, given a proliferation
in options and in the evidence base.
“GSK’s recent commitment to
supporting independent medical
education around such identified
gaps gave us the opportunity to
support this important program.
“Our new funding framework
guarantees the independence
of this education, developed
and delivered entirely at arm’s
length from GSK...we believe this
model has the potential to make a
meaningful difference for patients
in Australian primary care,” Dr
Weekes said.
Educational visits on the COPD
program have already started in
selected locations across Australia.
The above article was sent to subscribers in Pharmacy Daily's issue from 05 Aug 16To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 05 Aug 16
